-
Jan 3, 2025 | 
acrjournals.onlinelibrary.wiley.com | Lisa K Stamp |Chris Frampton |Sarah Stewart |Keith J. Petrie |N Lawrence Edwards |Angelo L. Gaffo | +1 more
Supporting Information Filename Description acr25494-sup-0001-Disclosureform.pdfPDF document, 405.2 KB Disclosure Form acr25494-sup-0002-TableS1.docxWord 2007 document , 22.4 KB Supplementary Table 1: Baseline demographics of the participants. Data are presented as n (%) or mean (SD) unless otherwise stated.
-
Dec 23, 2024 | 
acrjournals.onlinelibrary.wiley.com | Lisa K Stamp |Christopher Frampton |Jeff Newcomb |James R. O'Dell |Ted R Mikuls |Nicola Dalbeth
Supporting Information Filename Description acr25486-sup-0001-Disclosureform.pdfPDF document, 408.1 KB Disclosure Form
-
Nov 23, 2024 | 
the-rheumatologist.org | Lisa K Stamp
ACR CONVERGENCE 2024—Approximately 70 abstracts about gout from around the globe were accepted for presentation at ACR Convergence 2024. My picks reflect my passion and interests in improving gout management. Industry-led clinical trials play an important role in drug development and regulatory approvals. As clinicians, we rely on clinical trial data to guide our treatment decisions and to develop treatment recommendations and consensus guidelines.
-
Nov 5, 2024 | 
nature.com | Tanya J. Major |Riku Takei |Yuya Shirai |Wei Qing Wang |Murray Cadzow |Amanda Phipps-Green | +35 more
Correction to: Nature Genetics https://doi.org/10.1038/s41588-024-01921-5. Published online 15 October 2024. In the version of the article originally published, there were errors in the consortium lists at the end of the paper. Maureen Rischmueller, Hyon K. Choi, Masahiro Nakatochi, Jeff N. Miner, Daniel H. Solomon, Kathleen M. Giacomini and Deanna J. Brackman were erroneously listed as members of the Japan Gout Genomics Consortium.
-
Oct 28, 2024 | 
bmjmedicine.bmj.com | Neil Chanchlani |Lisa K Stamp |Andrew Day |Vivien Lou Chen
Low certainty evidence suggests a proactive approach during maintenance therapy for patients treated with infliximabAbout 1% of adults and children globally,1 and between 5% and 7% of those living in western societies,2 have a chronic immune mediated inflammatory condition. Infliximab and adalimumab, which are anti-tumour necrosis factor (TNF) treatments, are the most widely used biologics for treating immune mediated inflammatory disorders.
-
Oct 15, 2024 | 
nature.com | Tanya J. Major |Riku Takei |Yuya Shirai |Wei Qing Wang |Murray Cadzow |Amanda Phipps-Green | +35 more
AbstractGout is a chronic disease that is caused by an innate immune response to deposited monosodium urate crystals in the setting of hyperuricemia. Here, we provide insights into the molecular mechanism of the poorly understood inflammatory component of gout from a genome-wide association study (GWAS) of 2.6 million people, including 120,295 people with prevalent gout. We detected 377 loci and 410 genetically independent signals (149 previously unreported loci in urate and gout).
-
Sep 23, 2024 | 
acrjournals.onlinelibrary.wiley.com | Suz Jack Chan |Lisa K Stamp |Gareth J Treharne |Nicola Dalbeth
Supporting Information Filename Description acr25437-sup-0001-Disclosureform.docxWord 2007 document , 92.1 KB Disclosure Form acr25437-sup-0002-supinfo.docxWord 2007 document , 459.6 KB Supporting Information
-
Sep 22, 2024 | 
acrjournals.onlinelibrary.wiley.com | Suz Jack Chan |Lisa K Stamp |Gareth J Treharne |Nicola Dalbeth
INTRODUCTION Current treatment paradigms for managing rheumatoid arthritis (RA) aim to prevent joint damage and disability by frequently assessing disease activity and altering disease-modifying antirheumatic drug (DMARD) therapy to achieve either remission or low disease activity (LDA).1 Since the introduction of biologic DMARDs (bDMARDs), more people with RA are able to achieve a state of LDA or remission.2 Although bDMARDs are effective, their high cost and adverse event profile have led...
-
Aug 21, 2024 | 
jamanetwork.com | Pascal Richette |Nicola Dalbeth |Lisa K Stamp
Surrogate Markers and Clinical Outcomes Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments Joshua D. Wallach, PhD, MS; Samuel Yoon, BS, BA; Harry Doernberg, MM; Laura R. Glick, MD; Oriana Ciani, PhD; Rod S. Taylor, PhD; Maryam Mooghali, MD; Reshma Ramachandran, MD, MHS, MPP; Joseph S. Ross, MD, MHS Surrogate Markers and Clinical Outcomes—Reply Joshua D. Wallach, PhD, MS; Reshma Ramachandran, MD, MPP, MHS; Joseph S.
-
Jun 2, 2024 | 
jrheum.org | Lisa K Stamp |Nicola Dalbeth |N. Dalbeth |L.K. Stamp
Key Indexing Terms:allopurinolgoutGout remains one of the most common forms of arthritis worldwide. Typically, gout presents with intermittent, intensely inflammatory gout flares, which represent the immune response to the deposition of monosodium urate (MSU) crystals within and around joints and periarticular structures.
